Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line treatment of HER- metastatic breast cancer with eribulin and bevacizumab
2013-001710-15Phase 2Completed
- Sponsor
- Arcagy-Gineco
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eribulin and bevacizumab in breast cancer, sponsored by Arcagy-Gineco. Primary endpoint: Progression-free survival at 1 year. Started Jun 2013; status: completed.
02
Drugs
eribulinbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2013-001710-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001710-15.